Empowering Neurodegenerative Disease Research

Neurodegenerative diseases are projected to triple by 2050, creating significant financial and emotional burdens for patients, caregivers, and healthcare systems. Current diagnostics for neurodegenerative diseases are limited by non-specific symptoms, delayed diagnosis, and high testing costs, highlighting the need for accessible blood-based assays. Beckman Coulter is developing highly sensitive, easy-to- use immunoassays to improve testing accessibility and clinical decision-making for neuro- degenerative disorders. Through partnerships with world-class research centers, Beckman Coulter advances understanding of biomarkers in conditions such as Alzheimer’s disease. Scalable, blood-based diagnostics can transform neurodegene- rative disease management, enabling earlier detection and better patient outcomes. Our research-use-only (RUO) neurology assays run on Beckman Coulter immunoassay analyzers, including the DxI9000, enabling high-throughput and automated testing for neurodegenerative-disease biomarker research.